Royce & Associates LP Purchases 31,482 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Royce & Associates LP increased its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 19.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 197,372 shares of the company’s stock after acquiring an additional 31,482 shares during the period. Royce & Associates LP owned about 0.23% of Pediatrix Medical Group worth $2,288,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Pediatrix Medical Group by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after buying an additional 164,333 shares during the period. Rubric Capital Management LP raised its position in shares of Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after acquiring an additional 7,241,400 shares during the last quarter. Boston Partners lifted its stake in shares of Pediatrix Medical Group by 34.0% in the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after acquiring an additional 453,254 shares during the period. Dana Investment Advisors Inc. boosted its holdings in Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after acquiring an additional 455,785 shares during the last quarter. Finally, Brandes Investment Partners LP increased its position in Pediatrix Medical Group by 12.8% during the 2nd quarter. Brandes Investment Partners LP now owns 735,068 shares of the company’s stock valued at $5,438,000 after purchasing an additional 83,588 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

Insider Activity

In other news, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the transaction, the chief executive officer now owns 170,001 shares in the company, valued at $1,834,310.79. This trade represents a 6.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the sale, the executive vice president now owns 135,810 shares of the company’s stock, valued at $2,172,960. This trade represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,808 shares of company stock worth $751,277 over the last three months. 1.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on MD. Jefferies Financial Group boosted their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday, November 13th. Mizuho increased their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Tuesday. Truist Financial boosted their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Finally, UBS Group raised their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $16.10.

Pediatrix Medical Group Stock Up 0.8 %

MD stock opened at $14.59 on Wednesday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. Pediatrix Medical Group, Inc. has a fifty-two week low of $6.62 and a fifty-two week high of $16.41. The stock’s 50 day simple moving average is $12.69 and its 200 day simple moving average is $9.93. The company has a market cap of $1.25 billion, a P/E ratio of -4.77, a price-to-earnings-growth ratio of 2.03 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. Pediatrix Medical Group’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the business earned $0.29 EPS. On average, research analysts expect that Pediatrix Medical Group, Inc. will post 1.25 earnings per share for the current fiscal year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.